Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 819-826

  Scott, Sarah M ^a   Brown, Myles ^b   Come, Steven E ^a  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

antiestrogen; breast cancer; estrogen receptor antagonist; estrogen receptors; fulvestrant; selective estrogen receptor modulator

Indexed keywords

ANASTROZOLE; FULVESTRANT; LETROZOLE; TAMOXIFEN;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTHROPATHY; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER PATIENT; CARDIOVASCULAR DISEASE; CELL DIVISION; CELL GROWTH; CELL SURVIVAL; CLINICAL EVALUATION; CONFIDENCE INTERVAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPLASIA; ESTROGEN THERAPY; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LEUKORRHEA; LOADING DRUG DOSE; MENOPAUSAL SYNDROME; MYALGIA; NAUSEA; OSTEOPOROSIS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; RISK; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; THROMBOEMBOLISM; VAGINITIS; VASODILATATION; VOMITING; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051956348     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.595560     Document Type: Article

References (47)

1. Normanno N, Di Maio M, De Maio E, et al; on behalf of the NCI-Naples Breast Cancer Group. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12:721-47
2. Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol 1987;112:R7-10
3. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000;7:17-28
4. Faslodex (fulvestrant) Injection [prescribing information]. AstraZeneca Pharmaceuticals LP; Wilmington, DC: 2004
5. Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: A novel component in autologous down-regulation. Mol Endocrinol 1999;13:1522-34
6. Nawaz Z, Lonard D, Dennis A, et al. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 1999;96:1858-62
7. Lonard D, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor- alpha transactivation. Mol Cell 2000;5:939-48
8. Wijayaratne AL, McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-92
9. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999;20:321-44
10. Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30
11. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73
12. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha- [9-(4,4,5,5,5- pentafluoropentylsulfinyl)- nonyl]estra-1,3,5, (10) triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-46
13. Lupien M, Meyer CA, Bailey ST, et al. Growth factor stimulation induces a distinct ERa cistrome underlying breast cancer endocrine resistance. Genes Dev 2010;24:2219-27
14. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006;13(Suppl 1):S15-24
15. Osborne CK, Jarman M, McCague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994;34:89-95
16. Osborne CK, Coronado-Heinsohn E, Hilsenbeck SG, et al. Comparison of the effects of the effects of a pure antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87(5):746-50
17. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/ TAMR-1. Cancer Res 1994;54:1587-95
18. Hu XF, Veroni M, De LM, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993;55:873-6
19. Howell A, DeFriend DJ, Blamey RW, et al. Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995;345(8941):911561-1
20. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20:3386-95
21. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403
22. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38
23. Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104:236-9
24. Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13
25. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 2008;26:1664-70
26. Robertson JFR. Fulvestrant (Faslodex®) - how to make a good drug better. Oncologist 2007;12:774-84
27. Pritchard KI, Rolski J, Papai Z, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010;123(2):453-61
28. Come SE, Parker LM, Wulf G, et al. Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer. J Clin Oncol 2009;27(Suppl 15); abstract 1050
29. Robertson JFR, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the FIRST study. J Clin Oncol 2009;27:4530-5
30. Robertson JFR, Lindemann JPO, Llombart-Cussac A, et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the 'FIRST' study. Abstract presented at the 33rd San Antonio Breast Cancer Symposium; 8 - 12 December 2010
31. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28(30):4594-600
32. Brodie A, Jelovac D, Sabnis G, et al. Model systems: Mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol 2005;95:41-8
33. Brodie A, Sabnis G, Jelovac D. Aromatase and breast cancer. J Steroid Biochem Mol Biol 2006;102:97-102
34. Long BJ, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004;96(6):456-65
35. Jelovac D, Macedo L, Goloubeva OG, et al. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44
36. Bergh J, Jonsson PE, Lidbrink E, et al. First results from FACT - An open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. Abstract presented at: 32nd Annual San Antonio Breast Cancer Symposium; 9 - 13 December 2009; San Antonio, TX
37. Robertson JFR, Dixon JM, Sibbering DM, et al. Tumor biomarker changes following pre-surgical treatment with 500 mg fulvestrant plus anastrozole versus 500 mg fulvestrant alone and 1 mg anastrozole alone. Abstract presented at: 32nd Annual San Antonio Breast Cancer Symposium; 9 - 13 December 2009; San Antonio, TX
38. ClinicalTrials.gov [Web site] Anastrozole With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal WomenWith Metastatic Breast Cancer. Available from: Http://www.clinicaltrials. gov/ct/show/NCT00075764 [Accessed 2 February 2010]
39. ClinicalTrials.gov [Web site]. Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. Available from: Http://www.clinicaltrials. gov/ct/show/NCT00253422 [Accessed 2 February 2010]
40. Young OE, Renshaw L, Macaskill EJ, et al. Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor positive primary breast cancer. Eur J Cancer 2008;44(3):391-9
41. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1-9
42. Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 2007;109:832-9
43. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-62
44. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28(27):4120-8
45. Macedo LF, Sabnis G, Brodie A. Preclinical modeling of endocrine response and resistance: Focus on aromatase inhibitors. Cancer 2008;112:679-88
46. Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen: Mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 2004;10:337S-45S
47. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877-83